Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series

Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series

Abstract Background Prior case series suggest that a 5-day course of oral Paxlovid (nirmatrelvir/ritonavir) benefits some people with Long COVID, within and/or outside of the context of an acute reinfection. To the best of our knowledge, there have been no prior case series of people with Long COVID...

Full description

Saved in:
Bibliographic Details
Main Authors: Alison K. Cohen, Toni Wall Jaudon, Eric M. Schurman, Lisa Kava, Julia Moore Vogel, Julia Haas-Godsil, Daniel Lewis, Samantha Crausman, Kate Leslie, Siobhan Christine Bligh, Gillian Lizars, JD Davids, Saniya Sran, Michael Peluso, Lisa McCorkell
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Communications Medicine
Online Access:https://doi.org/10.1038/s43856-024-00668-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s43856-024-00668-8

Similar Items